Page last updated: 2024-11-05

norgestrienone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Norgestrienone: A synthetic steroid with progestational and contraceptive activities. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13313
CHEMBL ID1908319
CHEBI ID135231
SCHEMBL ID146644
MeSH IDM0014986

Synonyms (42)

Synonym
unii-89386pyu9o
norgestrienona
norgestrienonum
89386pyu9o ,
nsc 101105
norgestrienone [inn:dcf]
19-nor-17alpha-pregna-4,9,11-trien-20-yn-3-one, 17-hydroxy-
norgestrienona [inn-spanish]
17-alpha-ethynyl-17-beta-hydroxyestra-4,9,11-trien-3-one
17-hydroxy-19-nor-17-alpha-pregna-4,9,11-trien-20-yn-3-one
brn 6230207
planor
17-hydroxy-19-nor-17alpha-pregna-4,9,11-trien-20-yn-3-one
einecs 212-698-6
19-nor-17-alpha-pregna-4,9,11-trien-20-yn-3-one, 17-hydroxy-
19-norpregna-4,9,11-trien-20-yn-3-one, 17-hydroxy-, (17-alpha)-
17alpha-ethynyltrienolone
norgestrienonum [inn-latin]
D07220
norgestrienone (inn)
r 2010
norgestrienone
848-21-5
nsc-101105
ethynyl trienolone
CHEBI:135231
A301 ,
CHEMBL1908319
SCHEMBL146644
norgestrienone [who-dd]
17-hydroxy-19-nor-17.alpha.-pregna-4,9,11-trien-20-yn-3-one
norgestrienone [inn]
norgestrienone [mi]
norgestrienone [mart.]
DB13563
GVDMJXQHPUYPHP-FYQPLNBISA-N
Q7051184
nsc 101105; ogyline; planor; r 2010; ru 2010
DTXSID30878491
CS-0034886
HY-111302
AKOS040753312

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A total of 3 male, sex mature rats was applicated ethinyl-norgestrienone during a 3 months period in low dosage (60 mug) per day and was studied with 5 control animals."( The effect of a synthetic progestine on the fine structure of the epididymal head (stereological analysis).
Bartsch, G; Rohr, HP; Wagner, I,
)
0.37
" 3 male mature rats were treated during a 3-month period in low dosage (60 mcg/day) and were studied with 5 control animals."( The effect of a synthetic progestine on the fine structure of the epididymal head (stereological analysis).
Bartsch, G; Rohr, HP; Wagner, I,
)
0.13
" It was concluded that the bleeding control was unsatisfactory with every dosage of R 2323 used in this study."( The effect of progestin R 2323 released from vaginal rings on ovarian function.
Johansson, ED; Luukkainen, T; Vartiainen, E; Victor, A, 1975
)
0.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
estrogenA hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals by binding to oestrogen receptors. The oestrogens are named for their importance in the oestrous cycle. The oestrogens that occur naturally in the body, notably estrone, estradiol, estriol, and estetrol are steroids. Other compounds with oestrogenic activity are produced by plants (phytoestrogens) and fungi (mycoestrogens); synthetic compounds with oestrogenic activity are known as xenoestrogens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
steroidAny of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID69853Relative binding affinity against Estrogen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID1150123Relative binding affinity to rabbit progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID162462Relative binding affinity to the progesterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID212922Relative binding affinity to the testosterone receptor.1994Journal of medicinal chemistry, Nov-11, Volume: 37, Issue:23
PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores.
AID162617Relative binding affinity against progestin receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID39454Relative binding affinity against androgen receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID126441Relative binding affinity for the mineralocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
AID74389Relative binding affinity against glucocorticoid receptor1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Correspondence analysis applied to steroid receptor binding.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-199038 (88.37)18.7374
1990's3 (6.98)18.2507
2000's2 (4.65)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 110.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index110.62 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.07 (4.65)
Search Engine Demand Index201.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (110.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (19.57%)5.53%
Reviews1 (2.17%)6.00%
Case Studies2 (4.35%)4.05%
Observational0 (0.00%)0.25%
Other34 (73.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]